Document Detail

Bivalirudin: a review of the pharmacology and clinical application.
MedLine Citation:
PMID:  21108549     Owner:  NLM     Status:  In-Process    
Among the current agents in the class of direct thrombin inhibitors, bivalirudin (Angiomax(®), The Medicines Company, NJ, USA) has seen increased use in cardiovascular medicine over the past decade through its primary indication as an anticoagulant used during percutaneous coronary interventions. Bivalirudin has been further investigated and used as the anticoagulation strategy in the setting of cardiac and endovascular surgical procedures and is frequently utilized in the management of patients with heparin-induced thrombocytopenia. In comparison with heparin, bivalirudin exhibits a low immunogenic profile and provides similar or reduced major bleeding rates as well as a predictable degree of anticoagulation that is dose related. Bivalirudin primarily undergoes dual elimination via proteolytic cleavage and renal elimination, and requires dose adjustment in the setting of severe renal dysfunction. Given the body of supportive data, bivalirudin is likely to continue to figure prominently as a reliable and efficient anticoagulation strategy. Additional agents in the class of direct thrombin inhibitors are under investigation and may find increasing clinical use.
David A Van De Car; Sunil V Rao; E Magnus Ohman
Related Documents :
10247959 - How much stress is too much?
21657099 - Homer and herodotus to egyptian medicine.
1096409 - Experimental evaluation of bladder closure techniques.
23831199 - Paul holland: contributions to transfusion medicine.
10847639 - Shock at the millennium. i. walter b. cannon and alfred blalock.
6991719 - Urinary tract undiversion in a patient with an areflexic neurogenic bladder: management...
8405519 - Evaluation of the impact of intraobserver variability on endometrial dating and the dia...
21920129 - Will the new consumer protection act prevent harm to nutritional supplement users?
2818309 - The management of emergencies in general practice.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  8     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1673-81     Citation Subset:  IM    
Duke University Medical Center, Division of Cardiology, 2301 Erwin Road, Durham, NC, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antihypertensive and organ-protective effects of benazepril.
Next Document:  New directions in device therapies among children and adults with congenital heart.